The endocannabinoid signaling system in cancer

Trends in Pharmacological Sciences

Volumn 34, Issue 5, 2013, Pages 273-282

  Pisanti, Simona ^a   Picardi, Paola ^a   D'Alessandro, Alba ^a   Laezza, Chiara ^b   Bifulco, Maurizio ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLGLYCEROL LIPASE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; LIPID; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE PHASE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; LIPID METABOLISM; LIPID RAFT; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR PATHOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ENDOCANNABINOIDS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84876924195     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2013.03.003     Document Type: Review

References (109)

1. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
2. C.R. Santos, and A. Schulze Lipid metabolism in cancer FEBS J. 279 2012 2610 2623
3. V. Di Marzo The endocannabinoid system and its therapeutic exploitation Nat. Rev. Drug Discov. 3 2004 771 784
4. V. Di Marzo Endocannabinoids: synthesis and degradation Rev. Physiol. Biochem. Pharmacol. 160 2008 1 24
5. R.G. Pertwee International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2 Pharmacol. Rev. 62 2010 588 631
6. S. Burstein The elmiric acids: biologically active anandamide analogs Neuropharmacology 55 2008 1259 1264
7. M.L. De Jesús Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas Neurochem. Int. 56 2010 829 833
8. M. Bifulco, and V. Di Marzo Targeting the endocannabinoid system in cancer therapy: a call for further research Nat. Med. 8 2002 547 550
9. S. Pisanti Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents Best Pract. Res. Clin. Endocrinol. Metab. 23 2009 117 131
10. G. Velasco Towards the use of cannabinoids as antitumour agents Nat. Rev. Cancer 12 2012 436 444
11. S. Petrosino, and V. Di Marzo FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels Curr. Opin. Investig. Drugs 11 2010 51 62
12. M.P. Endsley Expression and function of fatty acid amide hydrolase in prostate cancer Int. J. Cancer 123 2008 1318 1326
13. L. Hamtiaux Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism PLoS ONE 6 2011 e26823
14. L. Hamtiaux The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action BMC Cancer 12 2012 92
15. N. Olea-Herrero Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-methanandamide and JWH-015: involvement of CB2 Br. J. Cancer 101 2009 940 950
16. M.M. Caffarel Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition Mol. Cancer 9 2010 196 206
17. X.S. Xian Effect of a synthetic cannabinoid agonist on the proliferation and invasion of gastric cancer cells J. Cell. Biochem. 110 2010 321 332
18. J.M. Park Antiproliferative mechanism of a cannabinoid agonist by cell cycle arrest in human gastric cancer cells J. Cell. Biochem. 112 2011 1192 1205
19. A. Preet Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis Cancer Prev. Res. (Phila.) 4 2011 65 75
20. G. Aviello Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer J. Mol. Med. (Berl.) 90 2012 925 934
21. B. Bosier Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB1 receptor Br. J. Pharmacol. 155 2008 24 33
22. C. Laezza Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells Endocr. Relat. Cancer 17 2010 495 503
23. S. Sarfaraz Cannabinoid receptor as a novel target for the treatment of prostate cancer Cancer Res. 65 2005 1635 1641
24. C. Laezza Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells FEBS Lett. 580 2006 6076 6082
25. M.M. Caffarel Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation Cancer Res. 66 2006 6615 6621
26. S. Sarfaraz Cannabinoids for cancer treatment: progress and promise Cancer Res. 68 2008 339 342
27. M. Bifulco Endocannabinoids in endocrine and related tumors Endocr. Relat. Cancer 15 2008 391 408
28. S. Sreevalsan Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent Anticancer Res. 31 2011 3799 3807
29. M.M. Caffarel Cannabinoids: a new hope for breast cancer therapy? Cancer Treat. Rev. 38 2012 911 918
30. M. Salazar Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells J. Clin. Invest. 119 2009 1359 1372
31. A. Shrivastava Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy Mol. Cancer Ther. 10 2011 1161 1172
32. D. Vara Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy Cell Death Differ. 18 2011 1099 1111
33. F. Cianchi Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells Clin. Cancer Res. 14 2008 7691 7700
34. R. Mechoulam, and E. Shohami Endocannabinoids and traumatic brain injury Mol. Neurobiol. 36 2007 68 74
35. C. Grimaldi Anandamide inhibits adhesion and migration of breast cancer cells Exp. Cell Res. 312 2006 363 373
36. C. Laezza The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway Endocr. Relat. Cancer 15 2008 965 974
37. K. Nithipatikom Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells Endocrinology 153 2012 29 41
38. D.J. Hermanson, and L.J. Marnett Cannabinoids, endocannabinoids, and cancer Cancer Metastasis Rev. 30 2011 599 612
39. M.L. Casanova Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors J. Clin. Invest. 111 2003 43 50
40. C. Blázquez Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas Cancer Res. 64 2004 5617 5623
41. C. Laezza Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells Eur. J. Cancer 48 2012 3112 3122
42. N.M. Curran The synthetic cannabinoid R(+)WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner J. Biol. Chem. 280 2005 35797 35806
43. C. Blázquez Inhibition of tumor angiogenesis by cannabinoids FASEB J. 17 2003 529 531
44. M. Solinas Cannabidiol inhibits angiogenesis by multiple mechanisms Br. J. Pharmacol. 167 2012 1218 1231
45. O. Asimaki, and D. Mangoura Cannabinoid receptor 1 induces a biphasic ERK activation via multiprotein signaling complex formation of proximal kinases PKCβ, Src, and Fyn in primary neurons Neurochem. Int. 58 2010 135 144
46. O. Asimaki Cannabinoid 1 receptor-dependent transactivation of fibroblast growth factor receptor 1 emanates from lipid rafts and amplifies extracellular signal-regulated kinase 1/2 activation in embryonic cortical neurons J. Neurochem. 116 2011 866 873
47. S. Pisanti Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis Blood 117 2011 5541 5550
48. M.W. Nasser Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion PLoS ONE 6 2011 e23901
49. F. Rossi The 17-β-oestradiol inhibits osteoclast activity by increasing the cannabinoid CB2 receptor expression Pharmacol. Res. 68 2012 7 15
50. M.C. Proto Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth J. Cell. Physiol. 227 2012 250 258
51. I. Brown Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators Prog. Lipid Res. 52 2012 80 109
52. S. Karaliota Anandamide increases the differentiation of rat adipocytes and causes PPARγ and CB1 receptor up-regulation Obesity 17 2009 1830 1838
53. O. Gomez Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways Br. J. Pharmacol. 163 2011 1520 1532
54. E.J. Williams The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response J. Cell Biol. 160 2003 481 486
55. D. Sarnataro Plasma membrane and lysosomal localization of CB1 cannabinoids receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells FEBS Lett. 579 2005 6343 6349
56. S. DeMorrow Opposing actions of endocannabinoids on cholangiocarcinoma growth, recruitment of Fas and Fas ligand to lipid rafts J. Biol. Chem. 282 2007 13098 13113
57. D. Sarnataro The cannabinoid CB1 receptor antagonist rimonabant (SR 141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism Mol. Pharmacol. 70 2006 1298 1306
58. M. Notarnicola Estrogenic induction of cannabinoids CB1 receptor in human colon cancer cell lines Scand. J. Gastroenterol. 43 2008 66 72
59. A. Lenman, and C.J. Fowler Interaction of ligands for the peroxisome proliferator-activated receptor γ with the endocannabinoid system Br. J. Pharmacol. 151 2007 1343 1351
60. C. Sánchez Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor Cancer Res. 61 2001 5784 5789
61. K. Gustafsson Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation Int. J. Cancer 123 2008 1025 1033
62. M.L. De Jesus Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas Neurochem. Int. 56 2010 829 833
63. D. Wang Loss of cannabinoid receptor 1 accelerates intestinal tumor growth Cancer Res. 68 2008 6468 6476
64. S.B. Gustafsson High tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II microsatellite stable colorectal cancer PLoS ONE 6 2011 e23003
65. C.W. Michalski Cannabinoids in pancreatic cancer: correlation with survival and pain Int. J. Cancer 122 2008 742 750
66. 1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer Eur. J. Cancer 45 2009 174 182
67. X. Xu Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma Cancer Genet. Cytogenet. 171 2006 31 38
68. M. Bifulco Cannabinoids and cancer: pros and cons of an antitumour strategy Br. J. Pharmacol. 148 2006 123 135
69. L. Thors Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4 PLoS ONE 5 2010 e12275
70. V. Di Marzo, and S. Petrosino Endocannabinoids and the regulation of their levels in health and disease Curr. Opin. Lipidol. 18 2007 129 140
71. K. Jin Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice Mol. Pharmacol. 66 2004 204 208
72. B. Mukhopadhyay Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver Proc. Natl. Acad. Sci. U.S.A. 108 2011 6323 6328
73. Q. Yang Anandamide induces cell death through lipid rafts in hepatic stellate cells J. Gastroenterol. Hepatol. 25 2010 991 1001
74. A.M. Malfitano Update on the endocannabinoid system as an anticancer target Expert Opin. Ther. Targets 15 2011 297 308
75. G. Portella Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis FASEB J. 17 2003 1771 1773
76. J. Flygare Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma FEBS Lett. 579 2005 6885 6889
77. A. Santoro Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon Int. J. Cancer 125 2009 996 1003
78. S. Pisanti, and M. Bifulco Endocannabinoid system modulation in cancer biology and therapy Pharmacol. Res. 60 2009 107 116
79. M. Bifulco, and S. Pisanti End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion Nat. Rev. Drug Discov. 8 2009 594
80. 1 receptor antagonists Trends Pharmacol. Sci. 32 2011 270 280
81. M. Laé Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas J. Pathol. 212 2007 143 151
82. S. Oesch Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma Mol. Cancer Ther. 8 2009 1838 1845
83. A.D. Marshall PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis Cancer Res. 71 2011 7471 7480
84. R. Piñeiro The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation Oncogene 30 2011 142 152
85. C. Andradas The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK Oncogene 30 2011 245 252
86. E. Pérez-Gómez The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas Oncogene 2012 10.1038/onc.2012.278
87. L.A. Ford A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells Br. J. Pharmacol. 160 2010 762 771
88. M. Karlsson cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases J. Biol. Chem. 272 1997 27218 27223
89. L. Huang Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor Lab. Invest. 91 2011 1007 1017
90. A. Lass Lipolysis - a highly regulated multi-enzyme complex mediates the catabolism of cellular fat stores Prog. Lipid Res. 50 2011 14 27
91. T.P. Dinh Brain monoglyceride lipase participating in endocannabinoid inactivation Proc. Natl. Acad. Sci. U.S.A. 99 2002 10819 10824
92. J.L. Blankman A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol Chem. Biol. 14 2007 1347 1356
93. D.K. Nomura Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis Cell 140 2010 49 61
94. L. Ye Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer Cancer Lett. 307 2011 6 17
95. D.K. Nomura Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer Chem. Biol. 18 2011 846 856
96. C.J. Fowler Monoacylglycerol lipase - a target for drug development? Br. J. Pharmacol. 166 2012 1568 1585
97. J.Z. Long Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects Nat. Chem. Biol. 5 2009 37 44
98. I.A. Khasabova Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain Pharmacol. Res. 64 2011 60 67
99. M.A. Sticht Inhibition of monoacylglycerol lipase attenuates vomiting in Suncus murinus and 2-arachidonoyl glycerol attenuates nausea in rats Br. J. Pharmacol. 165 2012 2425 2435
100. J.E. Schlosburg Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system Nat. Neurosci. 13 2010 1113 1119
101. R. Ramer COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells Mol. Cancer Ther. 12 2013 69 82
102. M.I. Rudolph The influence of mast cell mediators on migration of SW756 cervical carcinoma cells J. Pharmacol. Sci. 106 2008 208 218
103. 9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo Oncogene 27 2008 339 346
104. S.D. McAllister Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis Breast Cancer Res. Treat. 129 2011 37 47
105. L. Soroceanu Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target Cancer Res. 73 2013 1559 1569
106. N.M. Kogan A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells Mol. Pharmacol. 70 2006 51 59
107. S. Pisanti Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy J. Cell. Physiol. 211 2007 495 503
108. R. Ramer, and B. Hinz Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1 J. Natl. Cancer Inst. 100 2008 59 69
109. C. Blázquez Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity? Neuropharmacology 54 2008 235 243